AHK-Cu vs GHK-Cu: Which Copper Peptide Is for Skin and Which Is for Hair?
Start with our pillar guide: Argireline vs Matrixyl: Mechanisms, Trials and Which to Use, or browse all Reviews & Comparisons articles.
AHK-Cu vs GHK-Cu comes down to thin evidence on both sides. Vendors sell GHK-Cu for skin and AHK-Cu for hair, which roughly matches where the research sits, but neither is proven in people to the standard the marketing implies. AHK-Cu has no human studies, and no study has compared them head to head.
Evidence: Limited (GHK-Cu); Lab / animal only (AHK-Cu).
This page covers the comparison only. For AHK-Cu basics, see our companion guide to the AHK-Cu peptide and its hair growth evidence. For the better-studied relative, see our pillar guide to copper peptides for skin.
Key takeaways
- GHK-Cu's evidence base: a 2026 systematic review of GHK-Cu in aesthetic medicine found 20 studies, 18 preclinical and 2 RCTs (Mokhtar et al., 2026).
- AHK-Cu's evidence base: the only AHK-Cu study used human hair follicles ex vivo and cultured dermal papilla cells. It included no people (Pyo et al., 2007).
- A 2026 evidence-mapping review keeps GHK-Cu separate from other copper peptides and calls its clinical evidence "sparse," so AHK-Cu can't borrow GHK-Cu's data (Mateescu et al., 2026).
- Penetration: GHK-Cu is "a fairly hydrophilic compound with limited permeation through the lipophilic stratum corneum" (Ogórek et al., 2025). No penetration data exist for AHK-Cu.
- Natural presence: GHK occurs in human serum at about 200 ng/ml at age 20 and about 80 ng/ml by age 60 (Dou et al., 2020). No serum level has been reported for AHK.
What's the difference between AHK-Cu and GHK-Cu?
The 2 peptides differ by 1 amino acid. AHK-Cu starts with alanine and GHK-Cu starts with glycine, and both carry copper. The bigger difference is the evidence: GHK-Cu has a small clinical literature, while AHK-Cu has 1 lab study.
AHK-Cu is L-alanyl-L-histidyl-L-lysine bound to copper (Cu2+) (Pyo et al., 2007). GHK-Cu is glycyl-L-histidyl-L-lysine bound to copper(II) (Mateescu et al., 2026). On ingredient lists, GHK-Cu appears under its INCI name (the standardized cosmetic ingredient name) copper tripeptide-1, per the EU CosIng database. Vendors often label AHK-Cu "copper tripeptide-3," but we couldn't confirm that name in CosIng ourselves.
A small change in sequence can change how a peptide binds copper and behaves in the body. That is why the 2026 review grouped "canonical GHK-Cu" apart from "non-GHK copper-peptide systems" (Mateescu et al., 2026). Results for one don't transfer to the other.
| Feature | AHK-Cu | GHK-Cu |
|---|---|---|
| Sequence | Alanine-histidine-lysine + copper (Cu2+) | Glycine-histidine-lysine + copper (Cu2+) |
| Ingredient-list name | Vendors say copper tripeptide-3; not confirmed by us in CosIng | Copper tripeptide-1 (CosIng) |
| Main marketed use | Hair and scalp | Skin aging and repair |
| Human studies | None | 2 RCTs in a 2026 systematic review; small cosmetic studies (13 and 18 participants) |
| Lab or animal studies | 1 study: human follicles ex vivo + cultured dermal papilla cells | 18 preclinical studies in a 2026 systematic review |
| Penetration data | None | Hydrophilic; almost none crossed intact human skin in 9 h (in vitro) |
| Safety data | None specific to AHK-Cu | No peptide-specific patch data; copper-salt patch tests apply to copper in general |
| Natural presence in the body | Not reported | In human serum, ~200 ng/ml at 20, ~80 ng/ml by 60 |
| Typical product forms | Hair serums; research-use powders | Face serums and creams; research-use powders and injectables |
Bottom line: GHK-Cu has more data, but neither is proven in people. No study has compared them directly.
Evidence: Limited (GHK-Cu); Lab / animal only (AHK-Cu).
AHK-Cu vs GHK-Cu: which is better for skin?
GHK-Cu has the only skin data of the 2, and even those are thin. No study has tested AHK-Cu on skin at all.
A 2026 PRISMA systematic review searched 3 databases through March 2026 and included 20 studies of GHK-Cu as a standalone aesthetic treatment: 18 preclinical and 2 RCTs (Mokhtar et al., 2026). The abstract reports that, clinically, GHK-Cu improved patient-reported satisfaction after laser resurfacing and reduced wrinkle volume and depth compared with controls. The authors also wrote that the findings were constrained by "a limited number of well-designed clinical trials." The abstract doesn't give trial sizes or funding.
Other reviews are more cautious. A 2026 evidence-mapping review concluded that GHK-Cu's clinical evidence "remains sparse and does not meet contemporary active-entity quality standards." It noted that a 13-participant post-CO2-laser study was negative on objective endpoints (Mateescu et al., 2026). A 2025 review found "a surprising absence of clinical studies" for topical GHK-Cu and its palmitoylated form, Pal-GHK, despite strong cell data (Mortazavi et al., 2025).
For AHK-Cu, the only skin-related line in the literature is background text. The Pyo paper's introduction says the tripeptide-copper complex stimulates dermal fibroblast proliferation and VEGF production (Pyo et al., 2007). That is a statement about prior work, not an AHK-Cu skin study. We compare GHK-Cu with a peptide that has more trial data in Matrixyl vs copper peptides, and rank skin peptides in our peptide ingredients guide.
Evidence: Limited (GHK-Cu for skin); no data (AHK-Cu for skin).
AHK-Cu vs GHK-Cu for hair growth: which has the evidence?
Neither peptide is proven for hair in people. AHK-Cu's hair growth case rests on 1 lab study, and GHK-Cu's on 1 small, poorly characterized eyebrow study plus a multi-ingredient injection trial.
AHK-Cu hair growth: the one study
Pyo et al. (2007) tested AHK-Cu on human hair follicles kept alive in organ culture (ex vivo) and on cultured dermal papilla cells (DPCs, the specialized cells at the follicle base that help drive hair growth). At 10⁻¹² to 10⁻⁹ M, AHK-Cu lengthened follicles and increased DPC proliferation. At 10⁻⁹ M it reduced the number of dying DPCs, "but this decrease was not statistically significant," while markers linked to cell survival shifted in a favorable direction. The authors "proposed" that AHK-Cu supports follicle growth this way.
The abstract doesn't report sample size, duration or conflicts, and PubMed lists non-US-government research support without naming the funder. These picomolar-to-nanomolar lab concentrations can't be converted into a percentage in a serum. We cover this study in detail in our AHK-Cu peptide guide. Evidence: Lab / animal only.
GHK-Cu and hair
The 2026 evidence map describes an 18-participant split-face eyebrow study that reported positive cosmetic hair outcomes but "did not define GHK-Cu speciation or local exposure" (Mateescu et al., 2026). In other words, it's unclear what form of copper peptide the eyebrows actually received. Evidence: Early / preliminary.
The largest study containing a copper peptide is an open-label, single-arm pilot in 1,000 patients who received scalp injections every 3 weeks for 8 sessions (Kapoor & Shome, 2018). Hair fall fell significantly in 83% on pull test, and total hair count rose at 1 year (P = 0.002). But the formulation also contained VEGF, bFGF, IGF, KGF and thymosin β4 alongside copper tripeptide-1, and there was no control group. The result can't be credited to the copper peptide, and it says nothing about AHK-Cu or about topical use. Evidence: Early / preliminary (for the mixture, not copper peptide alone).
What about animal data and minoxidil?
A 1993 review reported that an unnamed copper-binding peptide, PC1031, enlarged follicles on the backs of fuzzy rats with an effect "similar to that of topical minoxidil" (Uno & Kurata, 1993). The abstract doesn't identify PC1031 as AHK-Cu or GHK-Cu, and rat back skin is not a human scalp. Minoxidil itself is an established hair-loss treatment with far more human data than either copper peptide. If you're losing hair, a dermatologist can find the cause and talk through options. Our upcoming hub on copper peptides for hair covers the wider category.
Evidence: Lab / animal only (AHK-Cu); Early / preliminary (GHK-Cu).
GHK-Cu vs AHK-Cu: how do the evidence ladders compare?
GHK-Cu climbs further up the evidence ladder, reaching small human studies and 2 RCTs. AHK-Cu stops at the lab bench.
| Pyo et al., 2007 | Not reported (ex vivo human follicles + cultured DPCs) | Not reported | 10⁻¹² to 10⁻⁹ M in culture | Longer follicles; more DPC proliferation; drop in dying cells not significant |
| Human studies of AHK-Cu | 0 | None | None | No human study for hair or skin |
Pyo et al., 2007
Result: Longer follicles; more DPC proliferation; drop in dying cells not significant
The only AHK-Cu study. Lab only, no human participants. Funder not named in the abstract.
Human studies of AHK-Cu
Result: No human study for hair or skin
A 2026 evidence map separates non-GHK copper peptides from GHK-Cu, so GHK-Cu data don't apply to AHK-Cu.
Top rung reached: lab only. Evidence: Lab / animal only.
| Mokhtar et al., 2026 (systematic review) | 20 studies (18 preclinical, 2 RCTs) | Search to March 2026 | Varied | Preclinical matrix and repair effects; RCTs reported better post-laser satisfaction and wrinkle measures vs controls |
| Post-CO2-laser study (via Mateescu et al., 2026) | 13 | Not reported | Not reported | Negative on objective endpoints |
| Split-face eyebrow study (via Mateescu et al., 2026) | 18 | Not reported | GHK-Cu form and exposure not defined | Positive cosmetic hair outcomes |
| Kapoor & Shome, 2018 | 1,000 | 8 sessions every 3 weeks; follow-up to 1 year | Scalp injection; copper tripeptide-1 + 5 other actives | Less hair fall in 83%; hair count up at 1 year |
| Li et al., 2015 | In vitro human skin; cell and pig models | 9 hours | GHK-Cu with or without microneedles | Almost none crossed intact skin; microneedles raised permeation |
Mokhtar et al., 2026 (systematic review)
Result: Preclinical matrix and repair effects; RCTs reported better post-laser satisfaction and wrinkle measures vs controls
Authors note few well-designed clinical trials. Trial sizes and funding not given in the abstract.
Post-CO2-laser study (via Mateescu et al., 2026)
Result: Negative on objective endpoints
Reported in a 2026 evidence-mapping review.
Split-face eyebrow study (via Mateescu et al., 2026)
Result: Positive cosmetic hair outcomes
Small and poorly characterized.
Kapoor & Shome, 2018
Result: Less hair fall in 83%; hair count up at 1 year
Open-label, single-arm, no control. Effect can't be attributed to the copper peptide.
Li et al., 2015
Result: Almost none crossed intact skin; microneedles raised permeation
Penetration study, not an efficacy trial.
Top rung reached: small RCTs. Evidence: Limited.
The age decline is a real finding: GHK in serum averages about 200 ng/ml at 20 and about 80 ng/ml by 60 (Dou et al., 2020). Nobody has shown that applying GHK-Cu to the face restores those levels or that the decline causes visible aging. For AHK, no natural serum level has been reported.
Evidence: Limited (GHK-Cu); Lab / animal only (AHK-Cu).
Does either copper peptide get through the skin?
GHK-Cu barely crosses intact skin in lab tests, and AHK-Cu has never been measured. This matters for any serum, whether it's applied to the face or scalp.
GHK-Cu is highly hydrophilic (water-loving), with log D values (a measure of oil vs water preference) of −2.38 to −2.49 at pH 4.5–7.4 (Badenhorst et al., 2016). Through intact human skin in vitro, "almost no peptide or copper permeated" in 9 hours. After microneedle pretreatment, 134 nanomoles of peptide and 705 nanomoles of copper got through (Li et al., 2015). A 2025 review adds that skin transport of liposome-encapsulated GHK-Cu has "received little attention" (Ogórek et al., 2025).
AHK-Cu differs from GHK-Cu by 1 amino acid, but no study has measured whether that changes absorption. More on the general problem is in our explainer on whether peptides absorb into skin. Evidence: Lab / animal only.
Are AHK-Cu and GHK-Cu safe?
No safety study exists for AHK-Cu, and GHK-Cu has no peptide-specific patch-test data in our sources. What we do have are copper-salt patch tests, which suggest copper allergy is uncommon and usually not clinically important.
A review of copper hypersensitivity found a weighted average of 3.8% positive patch tests to copper among people with suspected exposure or related symptoms. The authors called copper "a very weak sensitizer" compared with other metals, though it can cause relevant allergy in a few selected cases (Fage et al., 2014). In 2,660 routine patch tests, copper was positive in 3.53%, compared with 21.02% for nickel (Wöhrl et al., 2001).
Show data table
| Metal | Positive tests (%) |
|---|---|
| Nickel | 21.02% |
| Palladium | 5.9% |
| Copper | 3.53% |
| Cobalt | 3.31% |
Copper reactions were strongly linked to nickel reactions. When 26 copper-positive patients were retested, only 38% reacted again, and the authors judged positive copper tests "usually of low clinical relevance" (Wöhrl et al., 2001). Again, these were copper salts, not AHK-Cu or GHK-Cu. In a lab microneedle study, GHK-Cu caused no obvious irritation in cell and pig models (Li et al., 2015).
Our copper peptide side effects guide covers reactions in more depth, and copper peptides ruined my skin covers the so-called copper uglies, for which no study exists. Evidence: Limited (copper salts, not peptides).
Serums vs powders vs injections: what are you actually buying?
Serums are sold as cosmetics, while "research-use only" powders and injectables sit in a gray market. The safety gap is widest for the gray-market forms.
Cosmetics make appearance claims and don't go through drug approval. We couldn't find any approval of AHK-Cu as a drug ingredient. Several suppliers that sell AHK-Cu and GHK-Cu as powders label them for research use, which means they're not intended for people.
A 2026 narrative review of peptides marketed direct to patients described a "gray market" of unapproved compounds, including GHK-Cu, "operating largely outside of regulatory oversight." It found "rigorous human safety data are scarce, and there is potential for serious harm to patients" (Mendias & Awan, 2026). AHK-Cu isn't named in that abstract, but it has even less human data than GHK-Cu.
The 1,000-patient injection study above used a defined multi-ingredient formulation in a clinical setting (Kapoor & Shome, 2018). That isn't the same as reconstituting a research powder at home, and its results don't carry over. Evidence: Limited.
Can you use AHK-Cu and GHK-Cu together?
No study has tested AHK-Cu and GHK-Cu together, in cells, animals or people. "Use both" bundles are a sales choice, not a tested protocol, and there is no evidence of synergy or of harm.
Both deliver copper, so combining them adds copper exposure by an amount nobody has measured. Because the peptides differ in sequence, you also can't assume they work through the same pathway or add up. The same untested status applies to pairing either with other actives, which a frequent reader question raises.
The sources: copper(II) with ascorbate generates reactive oxygen species in a lab system (Jomova et al., 2023), and L-ascorbic acid must be formulated below pH 3.5 to enter skin (Pinnell et al., 2001). GHK-Cu broke down under oxidative, basic and to a lesser extent acidic stress but stayed stable at pH 4.5–7.4 (Badenhorst et al., 2016). Retinol degrades under light, oxygen and metal ions (Wang et al., 2023). Keeping them apart is clinic convention built on that lab chemistry, not on skin trials. Evidence: Lab / animal only.
Where the evidence stops
- No head-to-head study of AHK-Cu vs GHK-Cu exists in any model, and no potency comparison has been made.
- AHK-Cu has 0 human studies for hair or skin, and no penetration, safety, dose or timeline data.
- GHK-Cu's human data are small: 2 RCTs in a 2026 review, a negative 13-person laser study and an uncharacterized 18-person eyebrow study.
- Lab concentrations can't be mapped to product strengths for either peptide.
- Safety data are copper-salt patch tests, not peptide data, and gray-market injectables lack rigorous human safety data.
FAQ
Is AHK-Cu or GHK-Cu better for hair loss?
Neither has been shown to treat hair loss in a controlled human trial. AHK-Cu's only study used human hair follicles and dermal papilla cells in the lab, and GHK-Cu's hair data are one small eyebrow study and a multi-ingredient injection study. Minoxidil is an established hair-loss treatment with far more human data, and a dermatologist can diagnose the cause of hair loss.
Can I use GHK-Cu on my scalp?
No published study has tested a topical GHK-Cu serum on the scalp. The closest data are an 18-participant eyebrow study with poorly defined GHK-Cu and an open-label scalp injection study in which copper tripeptide-1 was one of 6 active ingredients. Lab studies also show GHK-Cu passes poorly through intact skin.
Which is stronger, AHK-Cu or GHK-Cu?
No potency comparison exists. No study has tested AHK-Cu and GHK-Cu side by side in cells, animals or people, so any claim that one is stronger is a guess.
Do AHK-Cu and GHK-Cu cause copper uglies?
No study has measured the reaction people call copper uglies for either peptide. Patch-test data show copper is a weak sensitizer, with about 3.5% to 3.8% positive tests in patch-tested groups, but those tests used copper salts, not copper peptides.
Can I use copper peptides with retinol or vitamin C?
There is no skin study of either combination. Lab chemistry shows copper plus L-ascorbic acid can generate reactive oxygen species and metal ions can degrade retinol, so a common approach is to use copper peptides at a different time from vitamin C and on non-retinoid nights. The same reasoning applies to AHK-Cu, but it has never been tested.
Is copper tripeptide-1 the same as GHK-Cu?
Yes. Copper tripeptide-1 is the INCI ingredient-list name for GHK-Cu in the EU CosIng database. Vendors often call AHK-Cu copper tripeptide-3, but we could not confirm that name in CosIng ourselves.
Can I use AHK-Cu and GHK-Cu together?
No study has tested them together, so there is no evidence of extra benefit or of harm from combining them. Product bundles that pair them are a marketing choice, not a tested protocol.
Are AHK-Cu powders and injections the same as serums?
No. Serums are sold as cosmetics, while powders and injectables labeled for research use sit in a gray market that operates largely outside regulatory oversight. A 2026 review found rigorous human safety data for unapproved peptides such as GHK-Cu are scarce.
References
- Pyo HK, Yoo HG, Won CH, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Arch Pharm Res. 2007. Ex vivo human hair follicles and in vitro dermal papilla cells; n and duration not reported; PubMed lists non-US-government research support. https://pubmed.ncbi.nlm.nih.gov/17703734/
- Kapoor R, Shome D. Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth: safety and efficacy evaluation in a first-in-man pilot clinical study. J Cosmet Laser Ther. 2018. Open-label, single-arm pilot; n=1,000; 8 sessions every 3 weeks, follow-up to 1 year; multi-ingredient formulation including copper tripeptide-1; funding not reported in abstract. https://pubmed.ncbi.nlm.nih.gov/29482481/
- Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR. Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. Bioimpacts. 2025. Review. https://pubmed.ncbi.nlm.nih.gov/39963574/
- Mateescu DM, Gavrilescu DM, Mincioaga RI, et al. GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap. Pharmaceutics. 2026. Systematic evidence-mapping review through August 2026; no pooling. https://pubmed.ncbi.nlm.nih.gov/42797253/
- Mokhtar J, Mohamad B, Haddad J, et al. The Regenerative Potential of GHK-Cu in Aesthetic Medicine. Aesthet Surg J. 2026. PRISMA systematic review through March 2026; 20 studies (18 preclinical, 2 RCTs). https://pubmed.ncbi.nlm.nih.gov/42619529/
- Ogórek K, Nowak K, Wadych E, et al. Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes? Molecules. 2025. Review. https://pubmed.ncbi.nlm.nih.gov/39795193/
- Li H, Low YS, Chong HP, et al. Microneedle-Mediated Delivery of Copper Peptide Through Skin. Pharm Res. 2015. In vitro human skin permeation over 9 hours, with cell and pig safety models; PubMed lists non-US-government research support. https://pubmed.ncbi.nlm.nih.gov/25690343/
- Badenhorst T, Svirskis D, Wu Z. Physicochemical characterization of native glycyl-l-histidyl-l-lysine tripeptide for wound healing and anti-aging: a preformulation study for dermal delivery. Pharm Dev Technol. 2016. Lab stability and solubility study. https://pubmed.ncbi.nlm.nih.gov/25384620/
- Dou Y, Lee A, Zhu L, et al. The potential of GHK as an anti-aging peptide. Aging Pathobiol Ther. 2020. Journal article summarizing serum GHK levels and preclinical data. https://pubmed.ncbi.nlm.nih.gov/35083444/
- Uno H, Kurata S. Chemical agents and peptides affect hair growth. J Invest Dermatol. 1993. Review of macaque and rat studies; peptide PC1031 not identified. https://pubmed.ncbi.nlm.nih.gov/8326148/
- Fage SW, Faurschou A, Thyssen JP. Copper hypersensitivity. Contact Dermatitis. 2014. Review of copper patch-test data. https://pubmed.ncbi.nlm.nih.gov/25098945/
- Wöhrl S, Hemmer W, Focke M, et al. Copper allergy revisited. J Am Acad Dermatol. 2001. Analysis of 2,660 routine patch tests; 26 copper-positive patients retested. https://pubmed.ncbi.nlm.nih.gov/11712031/
- Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. Narrative review. https://pubmed.ncbi.nlm.nih.gov/41966639/
- Jomova K, Cvik M, Lauro P, et al. The role of redox active copper(II) on antioxidant properties of the flavonoid baicalein. J Inorg Biochem. 2023. Lab chemistry study of Cu(II)-ascorbate systems. https://pubmed.ncbi.nlm.nih.gov/37178556/
- Pinnell SR, Yang H, Omar M, et al. Topical L-ascorbic acid: percutaneous absorption studies. Dermatol Surg. 2001. Pig skin absorption study. https://pubmed.ncbi.nlm.nih.gov/11207686/
- Wang PHM, Agach M, Libii M, et al. An eco-friendly system for stabilization of retinol. Int J Cosmet Sci. 2023. Formulation stability study with skin-explant absorption and a 12-week cosmetic study. https://pubmed.ncbi.nlm.nih.gov/36853015/
Other sources (not efficacy evidence):
- European Commission CosIng database: entry for COPPER TRIPEPTIDE-1. https://ec.europa.eu/growth/tools-databases/cosing/
Disclosure: This article is for general information only. It is not medical advice. Peptide Skincare has no affiliate links in this article and received no payment from any manufacturer mentioned. Copper peptides sold as serums are cosmetics; powders and injectables labeled "research use only" are not sold for use on people. See a dermatologist to diagnose hair loss or a skin reaction.